62nd annual meeting of the american association for the study of liver diseases and american college of rheumatology annual meeting.
نویسنده
چکیده
daily. Patients receiving alisporivir as IFN-free treatment who achieved undetectable HCV–RNA levels (below 25 IU/mL) at week 4 continued with initial treatment. Patients with detectable HCV–RNA levels were given add-on IFN and continued with ALV plus PR triple therapy from week 6 to week 24. Dr. Pawlotsky reported a greater than 3 log reduction in mean HCV–RNA levels over the first 4 weeks with alisporivirbased, IFN-free therapy. Rapid virological responses (RVRs) were also achieved by 28% of the ALV1,000 patients, by 37% of ALV600R patients, and by 42% of those in the ALV800R group. Patients achieving RVRs with IFN-free treatment maintained responses to week 12, with a minimal incidence of viral rebound. From weeks 4 to 6, the proportion of patients who achieved un detectable HCV–RNA levels with alisporivir-based, IFN-free therapy further increased to 32%, 49%, and 46% in the ALV1000, ALV600R, and ALV800R groups, respectively. More patients had undetectable HCV–RNA levels with alisporivir plus ribavirin than with alisporivir alone. The rate was 71% for patients with lower baseline HCV–RNA levels (less than 800,000 IU/mL). However, for alisporivir patients who did not achieve RVRs by week 4, add-on IFN as triple therapy (alisporivir 600 mg daily + PR + IFN) from week 6 resulted in rapid HCV clearance, with more than 90% of patients having undetectable HCV–RNA levels at week 12. Markedly lower rates of flu-like symptoms (fatigue, pyrexia, myalgia, and arthralgia) were reported with alisporivir-based, IFN-free therapy, compared with treatment that included IFN. Overall, fewer AEs were reported in the alisporivir arm. There were no reports of grade 3 or 4 anemia. Dr. Pawlotsky commented, “Alisporivir once daily shows promise to become the first interferon-free oral treatment for a substantial proportion of treatment-naive G2/3 HCV patients.”
منابع مشابه
An Official Journal of the American College of Rheumatology
SUPPLEMENT 2011 ANNUAL SCIENTIFIC MEETING November 4–9, 2011 Chicago, Illinois AN OFFICIAL JOURNAL OF THE AMERICAN COLLEGE OF RHEUMATOLOGY Arthritis & Rheumatism V O L U M E 6 3 , N U M B E R 1 0 ( S U P P L E M E N T ) O C T O B E R 2 0 1 1 AMERICAN COLLEGE OF RHEUMATOLOGY ABSTRACT SUPPLEMENT American College of Rheumatology 75 Annual Scientific Meeting Association of Rheumatology Health Profe...
متن کاملAmerican College of Rheumatology 2015 Annual Meeting.
Key sessions at the meeting covered the effects and relationships of early remission, weight, corticosteroids, and anti-tumor necrosis factor agents in rheumatic diseases.
متن کاملAdvances in the treatment of rheumatoid arthritis and the spondyloarthropathies
The 70th Annual Scientific Meeting of the American College of Rheumatology (ACR) took place in Washington, DC, USA, from November 10–15, 2006. More than 13,000 attendees, a record number, which included over 9500 scientists, registered for the meeting. Approximately 2000 abstracts were presented, along with a number of state-ofthe-art lectures and topical symposia. While it is not feasible to r...
متن کاملAmerican College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting.
We present sessions on establishing key clinical trial outcomes in psoriatic arthritis and on delaying the radiographic progression of ankylosing spondylitis.
متن کاملAward Number : DAMD 17 - 00 - 2 - 0018 TITLE : Mechanisms in Chronic Multisymptom Illnesses
Presentations – (Note: All 2006 abstracts were presented in last year’s annual report.) 2007 (pdfs of each are appended) Clauw DJ, Belfer I, Max M, Williams DA, Gracely RH, McLean SA, Harris RE, Neely A, Bair E, Diatchenko L, Maixner W. Increased Frequency of the Minor Allele for beta-3 Adrenergic Receptors in Individuals with Fibromyalgia and Related Syndromes. Accepted by the American College...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- P & T : a peer-reviewed journal for formulary management
دوره 36 12 شماره
صفحات -
تاریخ انتشار 2011